1. Market Research
  2. > Pathology
About 1300 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • North America
  • United States

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • North America
  • United States

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States

Axillary Hyperhidrosis - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 53 pages

The Merger would create a pharmaceutical company focused on developing novel and differentiated prescription therapies addressing unmet patient needs in hyperhidrosis, cutaneous Tcell lymphoma, psoriasis, and other debilitating dermatologic disorders.

  • Dermatological Condition
  • Therapy
  • United States
  • Allergan plc
  • Bodor Laboratories, Inc.

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 96 pages

The drug candidate is in Phase I stage of development for diffuse large B cell lymphoma, mantle cell lymphoma, marginal zone lymphoma (third line therapy).

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • Epizyme, Inc.

Follicular Lymphoma - Pipeline Review, H2 2016

  • $ 2000
  • November 2016
  • 540 pages

Nordic Nanovector is developing betalutin for the treatment of non-Hodgkin B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy

Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2020

  • $ 3500
  • February 2020
  • 96 pages

The drug candidate is in Phase I stage of development for diffuse large B cell lymphoma, mantle cell lymphoma, marginal zone lymphoma (third line therapy).

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • Epizyme, Inc.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 77 pages

It is in Phase II stage for follicular lymphoma.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • United States

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform - Pipeline Review, H1 2020

  • $ 3500
  • February 2020
  • 131 pages

IT WAS ALSO UNDER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA), ACUTE LYMPHOBLASTIC LEUKEMIA (T- ALL OR B-ALL), LYMPHOMA, NODAL, EXTRANODAL, SPLENIC MARGINAL ZONE LYMPHOMA AND DIFFUSE LARGE BCELL LYMPHOMA, MANTLE CELL LYMPHOMA, FOLLICULAR

  • Cancer
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Bcl 2 Like Protein 1 - Pipeline Review, H1 2020

  • $ 3500
  • June 2020
  • 61 pages

In November 2007, Ascenta Therapeutics completed a Phase II clinical trial of AT-## in patients with relapsed or refractory B-cell malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/ Chronic Lym

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • AbbVie Inc.

Aminopeptidase N - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 58 pages

Ferreri, Head of the clinical research at the Lymphoma Unit of Scientific Institute San Raffaele Hospital in Milan, to illustrate NGR-hTNF activity used in combination with chemotherapy in refractory or resistant to standard treatments patients with brain lymphomas.

  • Endocrine Disease
  • Lymphoma
  • Therapy
  • United States
  • MolMed S.p.A.

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 100 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Autoimmune Disease
  • Biopharmaceutical
  • Lymphoma
  • Pharmaceutical
  • Therapy

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2020

  • $ 3500
  • June 2020
  • 68 pages

Key findings include: CA-## was demonstrated to be generally well-tolerated; patients enrolled to date include patients with tumor types of DLBCL, WM, marginal zone lymphoma, follicular lymphoma, and lymphoplasmacytic lymphoma.

  • Lymphoma
  • Pharmaceutical
  • Protein Therapy
  • Therapy
  • United States

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2020

  • $ 3500
  • June 2020
  • 104 pages

The Phase I portion of the study can include patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma and non-Hodgkin lymphoma (NHL) (including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell

  • Autoimmune Disease
  • Biopharmaceutical
  • Lymphoma
  • Pharmaceutical
  • Therapy

Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 178 pages

IT WAS UNDER DEVELOPMENT FOR THE TREATMENT OF MANTLE CELL LYMPHOMA.

  • Hospital
  • Lymphoma
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy

Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2019

  • $ 3500
  • August 2019
  • 62 pages

The FDA also granted Breakthrough Therapy designation for XALKORI for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.

  • Lung Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 78 pages

As of September 2017, the drug candidate was in Phase I stage for T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

  • Dementia
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy

Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 181 pages

IT WAS UNDER DEVELOPMENT FOR THE TREATMENT OF MANTLE CELL LYMPHOMA.

  • Hospital
  • Lymphoma
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy

Histone Deacetylase 8 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 48 pages

It is in Phase I stage of development for the treatment of relapsed or refractory B-cell non- Hodgkin lymphoma including diffuse large B-Cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, transformed indolent lymphoma and mu

  • Lymphoma
  • Therapy
  • China
  • Product Initiative
  • Chipscreen Biosciences Ltd

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 173 pages

As a third line therapy for follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), diffuse large B-cell lymphoma (DLBCL) and relapsed/ refractory acute m

  • Breast Cancer
  • Lymphoma
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on